BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly Prepares Global Launch of Weight Loss Pill Following Successful Clinical Trial
Eli Lilly Prepares Global Launch of Weight Loss Pill Following Successful Clinical Trial
18
3
BTCCSquare news:
Eli Lilly (LLY) is advancing toward regulatory approval for its oral weight loss medication after positive Phase III trial results showed 10.5% average weight reduction. The Indianapolis-based pharma giant plans a mid-2026 global rollout following FDA clearance, positioning the pill as a more accessible alternative to injectable Zepbound.
The obesity treatment market, projected to reach $150 billion by 2030, could see significant disruption from this development. Trial data demonstrated the dual efficacy of Lilly's compound, with participants achieving meaningful weight loss while managing Type 2 diabetes symptoms.
By:
